About New Element Medicine
New Element Medicine is a Healthcare company based in Zhenjiang (China) founded in 2012 by Shi Dongfang. Drugs for cancer and metabolic diseases are developed. New Element Medicine has raised $152.05 million across 5 funding rounds from investors including Livzon Pharmaceutical, Kaitai Capital and Fortune Capital Partners. Its chief executive, as recorded, is Shi Dongfang. New Element Medicine offers products and services including ABP-671 and ABP-745. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Atom Therapeutics Co. Ltd.
Company details
Founded in 2012 and based in Zhenjiang, China, the company operates in the biotechnology sector. Focus is placed on developing pharmaceutical products for cancer and metabolic conditions. Pipeline includes URAT-1 targeting gout and hyperuricemia, as well as ABP-6061 and ABP-431 for non-alcoholic steatohepatitis, gastric cancer, colon cancer, and breast cancer. Operations center on research and drug development.
- Headquarters Zhenjiang, China
- Founders Shi Dongfang
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website atombp.com
- Social LinkedIn X
- Legal Name Atom Therapeutics Co. Ltd.
- Total Equity Funding$152.05M (USD)
in 5 rounds
- Latest Funding Round$83M (USD), Series D
Oct 2023
- InvestorsLivzon Pharmaceutical
& 12 more
Products & Services of New Element Medicine
New Element Medicine offers a comprehensive portfolio of products and services, including ABP-671 and ABP-745.
Treats chronic gout and hyperuricemia through clinical trials.
Addresses acute gout with safety and efficacy in trials.
Funding Insights of New Element Medicine
New Element Medicine has successfully raised a total of $152.05M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $83 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $152.05M
- Total Rounds 5
- Last Round Series D — $83M
- Investors Count 13
All 5 funding rounds of New Element Medicine with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $83M | Series D | – | Kaitai Capital Management | |
| Jan 2022 | $47.2M | Series C | – | ShenZhen GTJA Investment Group | |
| Jan 2020 | $21.85M | Series B | – | Kaitai Capital Management, Livzon Pharmaceutical | – |
| Jun 2018 | Series A | – | Optimal Capital Management, Zhongyu Capital | – | |
| Jun 2017 | Series A | – | Kaitai Capital Management | – |
13 investors in total: 13 institutional.
Investors in New Element Medicine
New Element Medicine has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Livzon Pharmaceutical, Kaitai Capital and Fortune Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Kaitai Capital is engaged in innovation investment management services. | kaitaicapital.com | Hangzhou, China | ||
| nnfe.com.cn | ||||
| szgig.com | ||||
| ktcap.cn | ||||
Efung Capital is focused on global biopharmaceutical investments. | 2012 | efungcapital.com | Shenzhen, China | |
| cgcapital.com.cn | ||||
A real estate company focused on multifamily development is operated. | 1998 | fcpmiami.com | Coral Gables, United States | |
| huajinsc.cn | ||||
| unifgroup.com | ||||
| oriza.com.cn |
Investor details for New Element Medicine
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of New Element Medicine
1 people are tracked at New Element Medicine (1 in leadership).
| Name | Role | Group |
|---|---|---|
Shi Dongfang | Founder & CEO | Leadership |
Complete people profiles for New Element Medicine
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of New Element Medicine
3 dated milestones of New Element Medicine across 11 years, from founding to its latest funding, stage changes and deals.
- Founded New Element Medicine is founded.
- Funding First funding round.
- Funding Latest funding round, Series D, of $83.0M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about New Element Medicine
Complete news archive for New Element Medicine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about New Element Medicine
New Element Medicine was founded in 2012 and raised its 1st funding round 5 years after it was founded.
New Element Medicine is headquartered in Zhenjiang, China. It is registered at Zhenjiang, Jiangsu, China.
Shi Dongfang is the CEO of New Element Medicine, as recorded in our data. They have also founded this company.
New Element Medicine is a funded company, having raised a total of $152.05M across 5 funding rounds to date.
Founded in 2012 and based in Zhenjiang, China, the company operates in the biotechnology sector. Focus is placed on developing pharmaceutical products for cancer and metabolic conditions. Pipeline includes URAT-1 targeting gout and hyperuricemia, as well as ABP-6061 and ABP-431 for non-alcoholic steatohepatitis, gastric cancer, colon cancer, and breast cancer. Operations center on research and drug development.
New Element Medicine offers ABP-671 and ABP-745.
New Element Medicine has 13 investors. Key investors include Livzon Pharmaceutical, Kaitai Capital, Fortune Capital Partners, Huajin Securities, and NNFE.
New Element Medicine operates through Atom Therapeutics Co. Ltd..